Is Emulex in Major Turnaround?
Emulex has announced the preliminary financial results for the second quarter of its fiscal year 2015.
All Work
Chris Lange
How Analysts View Alcoa After Earnings
For the most part, analysts were positive on Alcoa following its earnings report, though somewhat critical of certain segments.
Why Analyst Sees Deep Value in Solar After Sell-Off
Credit Suisse has weighed in on the solar sector, and the firm believes the stocks can make solid gains in 2015.
Why Credit Suisse Sees Apple Shares Rising to $130
Credit Suisse upgraded Apple to Outperform and raised its target price on Tuesday. We also saw an increased outlook from Canaccord Genuity.
Mixed Signals From Semiconductor Short Interest
Recent short interest data show that investors seem to be growing marginally more optimistic on the semiconductor industry as a whole.
Short Interest in Biotechs Signals Optimism
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Alcoa Earnings Beat, but Is It Enough?
Alcoa kicked off the earnings season and reported its fourth-quarter results Monday after the market close.
Analyst Team Gets Even Colder on Alcatel-Lucent Prospects
ThinkstockAlcatel-Lucent SA (NYSE: ALU) was downgraded by Merrill Lynch to Underperform from Neutral. This was effectively the opposite of what Credit Suisse had done in the previous week when it raised Alcatel-Lucnet to Outperform…
Why Analyst Team Raised Windstream and Frontier to Buy — Dividends and Value
Merrill Lynch has upgraded Windstream Holdings and Frontier Communications to Buy ratings from Neutral.
Celgene Expects to More Than Triple Earnings by 2020
Celgene Corp. provided a preliminary look at its financials for 2014 but also gave its financial outlook for 2015 and far beyond at the Annual J.P. Morgan Healthcare Conference.
Is the Merger a Great Deal for Tekmira Shareholders?
Tekmira Pharmaceuticals and OnCore Biopharma have announced that they will merge to form a new company to develop a curative regimen for hepatitis B patients.
Lululemon Turnaround No Longer in Downward Dog
Lululemon Athletica has updated its guidance for its fourth quarter and the 2014 fiscal year in the wake of strong sales.
Is the Dollar Really Why Tiffany Lowered Earnings Expectations?
Tiffany reported lower-than-expected sales results for the two-month holiday period ended December 31, citing headwinds from a strong U.S. dollar.
Why SanDisk Unexpectedly Lowered Guidance
SanDisk, the leader in flash memory, announced on Monday that it is lowering its revenue guidance for its fiscal fourth quarter.
The Puzzling Upgrade of Yelp
Yelp has received an interesting upgrade from Merrill Lynch, which said the company as well positioned to capitalize on key Internet trends.
Has Agenus Run Too Much?
Agenus, in conjunction with Incyte, announced a global license for the development and commercialization of Agenus's proprietary Retrocyte Display antibody discovery platform.
Analysts Temper Bed Bath & Beyond Expectations
Bed Bath & Beyond reported mixed third-quarter results Thursday after the market close and analysts have already begun to weigh in.
Five Below Sales Go Under in the Fourth Quarter
Five Below announced increased sales from last year, but the total was less than previously guided. The retailer cited soft pre-Christmas sales.
Gilead Continues to Recover from Express Scripts Loss
Gilead Sciences was picked up by Anthem to provide its hepatitis C drug as the primary option for patients.
Unemployment Improves, Yet Labor Force Participation Hits Multiyear Low
The U.S. Department of Labor has released the Unemployment Situation Report for the month of December. Overall, there was a solid pace in December.